CV Sciences Q2 sales fall on regulatory pressure
CVSI•Key financial details
| Metric | Actual |
|---|---|
| Q2 Sales | $2.99 mln |
| Q2 Net Loss | $775,000 |
| Q2 Gross Profit | $1.45 mln |
| Q2 Operating Expenses | $1.75 mln |
| Q2 Operating Income | -$301,000 |
| Q2 Pretax Loss | $770,000 |
Outlook and result drivers
- The company says cost actions position it to improve profitability and generate positive cash flow as market conditions normalize.
- CV Sciences remains focused on disciplined capital allocation and operational excellence.
- The company says results remain pressured by a challenging regulatory and consumer environment.
Result drivers:
- Regulatory pressure - The company said lower sales volume was driven by restrictive regulations at the federal level and in certain states.
- New product contribution - The company said 44% of Q2 net revenue came from products launched since Jan. 1, 2023.
- Lower average prices - The company said it realized some minor decreases in average sales prices.
